Prime Medicine, Inc. (NYSE:PRME – Get Free Report) has received an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $13.50.
A number of research firms have recently weighed in on PRME. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Prime Medicine in a report on Friday. Wedbush reissued an “outperform” rating and set a $12.00 target price on shares of Prime Medicine in a report on Thursday, August 8th. Finally, StockNews.com raised Prime Medicine to a “sell” rating in a report on Wednesday, August 7th.
Get Our Latest Stock Analysis on PRME
Institutional Inflows and Outflows
Prime Medicine Price Performance
Shares of Prime Medicine stock opened at $4.03 on Tuesday. The business has a fifty day simple moving average of $3.93 and a two-hundred day simple moving average of $5.12. Prime Medicine has a 1 year low of $3.28 and a 1 year high of $9.86. The company has a market capitalization of $483.72 million, a price-to-earnings ratio of -1.87 and a beta of 2.18.
Prime Medicine (NYSE:PRME – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.06). As a group, equities analysts anticipate that Prime Medicine will post -1.75 earnings per share for the current fiscal year.
Prime Medicine Company Profile
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Read More
- Five stocks we like better than Prime Medicine
- How to Use the MarketBeat Stock Screener
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- Golden Cross Stocks: Pattern, Examples and Charts
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.